BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Year: 2025
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025CELEBRATION, Fla., Oct. 27, 2025 (GLOBE...
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025CELEBRATION, Fla., Oct. 27, 2025 (GLOBE...
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025CELEBRATION, Fla., Oct. 27, 2025 (GLOBE...
MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
TempraMed to Support Beyond Type 1’s Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the...
World-Renowned Surgeon and Entrepreneur Dr. Mandeep S. Dhalla Invests in DentScribe.ai and Joins as Strategic Advisor
Cross-specialty leader behind large-scale retina consolidation sees DentScribe's AI turning SOAP notes into the operating system for growth. SAN JOSE,...
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will...
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs...
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing...
Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025
Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac RecoveryMENLO PARK, Calif.--(BUSINESS WIRE)--#TFX--Jupiter Endovascular,...
EXPOSÉ: DEA’s Marijuana Licensing Scheme Exposed – MMJ BioPharma’s Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
Newly uncovered DEA agreements confirm what MMJ BioPharma Cultivation has argued for years - that the agency's own rules make...
mediCAD® 8 Revolutionizes Orthopedic and Trauma Planning with Intelligent AI Integration
mediCAD has a new orthopedic and trauma planning software release coming up with mediCAD® 8. It revolutionizes its previous software...
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and...
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in...